Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Compumedics Limited (CMP.AX)
Abbotsford, VIC, AU
Compumedics Limited is a global medical technology enterprise engaged in the full lifecycle of designing, producing, marketing, and distributing advanced diagnostic medical devices. Its market reach extends across Australia, the Asia Pacific region, the Americas, Europe, and the Middle East. The company's product portfolio is primarily focused on solutions for sleep and neurological disorders. For sleep diagnostics, offerings include sophisticated PSG:EEG amplification systems like the Grael 4K, portable recording units such as the Somté PSG and Siesta 802, wearable monitoring devices like Somfit/Somfit Pro, and transcutaneous monitors (e.g., TCM5 FLEX). In the field of neurology, Compumedics supplies devices like the ONsight A.V.S. for home ambulatory studies, a variety of EEG amplifiers (e.g., Grael 4K-EEG, Grael LT EEG), comprehensive long-term EEG monitoring systems (Neuvo 64-512 Channel LTM), and specialized EMG/EP systems (including Xegis Forte and Xegis G:NEO). Complementing its hardware, the company develops an extensive range of software, featuring the Profusion Sleep and EEG platforms, Profusion neXus 360 (a web-based system for patient data and lab management), a Multi-Modal Neuroimaging Suite, and workflow optimization tools like Profusion neXus Laboratory Management and Scheduler. Other software offerings include HD Digital Video integration and various specialized applications. Furthermore, Compumedics provides magnetoencephalography systems, cutting-edge brain research technologies, services for pharmaceutical clinical trials and research, as well as a diverse array of accessories and consumables crucial for diagnostic and research endeavors. Established in 1987, Compumedics Limited is based in Abbotsford, Australia, and functions as a subsidiary of D & DJ Burton Holdings Pty Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.82% | -1.82% | -5.26% | -18.18% | -25.00% | -19.40% | -8.47% | +74.19% | -28.95% | -32.50% | -46.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+2.7% Q4'25: +17.3% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%-268.4% Q4'25: +62.5% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-15.5% Q4'25: +5.8% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+1.4% Q4'25: +3.9% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+2.2% Q4'25: +8.1% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+2.6% Q4'25: +12.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×7.16× Q4'25: 1.49× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
Jun 2029 1 Rev. Ana. 1 EPS Ana. |
Jun 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
37.54M
est: 33.50M (+12.1%)
|
34.42M
est: 33.00M (+4.3%)
|
37.00M
est: 35.90M (+3.1%)
|
41.51M
est: 42.60M (-2.6%)
|
35.07M
est: 36.50M (-3.9%)
|
35.74M
est: 37.40M (-4.4%)
|
37.76M
est: 54.50M (-30.7%)
|
42.41M
est: 69.10M (-38.6%)
|
49.72M
est: 78.80M (-36.9%)
|
51.04M
est: 51.00M (+0.1%)
|
66.30M
66.30M – 66.30M
+30.0% YoY
|
79.70M
79.70M – 79.70M
+20.2% YoY
|
95.20M
95.20M – 95.20M
+19.4% YoY
|
116.40M
116.40M – 116.40M
+22.3% YoY
|
141.60M
141.60M – 141.60M
+21.6% YoY
|
| EBITDA |
4.85M
est: 899.9K (+438.5%)
|
2.70M
est: 886.5K (+204.3%)
|
4.18M
est: 837.9K (+398.4%)
|
5.78M
est: 1.14M (+404.7%)
|
-5.42M
est: 776.0K (-798.4%)
|
2.56M
est: -8.57M (+129.9%)
|
3.31M
est: -11.59M (+128.6%)
|
-5.05M
est: -13.87M (+63.6%)
|
2.79M
est: 2.12M (+31.8%)
|
1.94M
est: 1.37M (+41.5%)
|
1.78M
1.78M – 1.78M
+30.0% YoY
|
2.14M
2.14M – 2.14M
+20.2% YoY
|
2.56M
2.56M – 2.56M
+19.4% YoY
|
3.13M
3.13M – 3.13M
+22.3% YoY
|
3.80M
3.80M – 3.80M
+21.6% YoY
|
| EBIT |
3.21M
est: -120.7K (+2,760.1%)
|
1.42M
est: -118.9K (+1,292.5%)
|
3.69M
est: 1.50M (+146.9%)
|
5.35M
est: -153.5K (+3,584.1%)
|
-7.08M
est: 1.39M (-611.1%)
|
1.11M
est: -7.73M (+114.3%)
|
2.10M
est: -10.46M (+120.1%)
|
-6.07M
est: -12.51M (+51.5%)
|
1.22M
est: -283.9K (+529.3%)
|
714.0K
est: -183.8K (+488.5%)
|
-238.9K
-238.9K – -238.9K
-30.0% YoY
|
-287.2K
-287.2K – -287.2K
-20.2% YoY
|
-343.0K
-343.0K – -343.0K
-19.4% YoY
|
-419.4K
-419.4K – -419.4K
-22.3% YoY
|
-510.2K
-510.2K – -510.2K
-21.6% YoY
|
| Net Income |
3.27M
est: 3.62M (-9.6%)
|
1.31M
est: 908.6K (+43.6%)
|
2.78M
est: 1.38M (+102.2%)
|
4.02M
est: 4.00M (+0.5%)
|
-5.84M
est: 1.28M (-557.8%)
|
998.0K
est: -6.37M (+115.7%)
|
1.36M
est: -8.62M (+115.7%)
|
-6.12M
est: -10.31M (+40.6%)
|
-338.0K
est: -13.14M (+97.4%)
|
-1.27M
est: 1.82M (-170.0%)
|
2.73M
2.73M – 2.73M
+50.0% YoY
|
6.72M
6.72M – 6.72M
+146.7% YoY
|
9.27M
9.27M – 9.27M
+37.8% YoY
|
12.36M
12.36M – 12.36M
+33.3% YoY
|
16.35M
16.35M – 16.35M
+32.4% YoY
|
| SGA |
11.70M
est: 15.16M (-22.8%)
|
12.53M
est: 14.93M (-16.1%)
|
13.00M
est: 13.23M (-1.7%)
|
14.48M
est: 19.28M (-24.9%)
|
14.93M
est: 12.25M (+21.8%)
|
14.38M
est: 16.20M (-11.3%)
|
15.13M
est: 21.93M (-31.0%)
|
19.66M
est: 26.24M (-25.1%)
|
21.14M
est: 33.44M (-36.8%)
|
29.14M
est: 23.08M (+26.3%)
|
30.00M
30.00M – 30.00M
+30.0% YoY
|
36.07M
36.07M – 36.07M
+20.2% YoY
|
43.08M
43.08M – 43.08M
+19.4% YoY
|
52.67M
52.67M – 52.67M
+22.3% YoY
|
64.08M
64.08M – 64.08M
+21.6% YoY
|
| EPS |
0.02
est: 0.02 (-2.6%)
|
0.01
est: 0.01 (+48.0%)
|
0.02
est: 0.02 (-31.7%)
|
0.02
est: 0.02 (+3.2%)
|
-0.03
est: 0.01 (-375.0%)
|
0.01
est: 0.01 (-37.8%)
|
0.01
est: 0.04 (-80.3%)
|
-0.03
est: 0.07 (-151.6%)
|
0.00
est: 0.08 (-102.5%)
|
-0.01
est: 0.01 (-170.0%)
|
0.02
0.02 – 0.02
+50.0% YoY
|
0.04
0.04 – 0.04
+146.7% YoY
|
0.05
0.05 – 0.05
+37.8% YoY
|
0.07
0.07 – 0.07
+33.3% YoY
|
0.09
0.09 – 0.09
+32.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Francis Lawson | Chief Financial Officer, Company Secretary & Executive Director | 407.6K | male |
| Warwick Freeman | Chief Technology Officer | 344.9K | male |
| David Burton | Founder, Executive Chairman & Chief Executive Officer | 254.5K | — |
| Kerry Trent Hubick | Legal Counsel and Trademark, Patent & General Legal Attorney | 81.2K | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CMP.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
